Share Email Print
cover

Proceedings Paper

Using delayed chemiluminescence as a photodynamic therapy dose metric in vivo
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Photodynamic therapy (PDT) is an important method to treat tumor. It is known that singlet oxygen (1O2) is the main factor mediating cytotoxicity in PDT. The effectiveness of a PDT treatment is directly linked to the 1O2 produced in the target. So to control the dose of 1O2 is very important. Although the luminescence from 1O2 can be detected and is suggested as an indicator for evaluating photodynamic therapy, the inherited disadvantages limit its potential for in vivo applications. We have previously reported that chemiluminescence (CL) can be used to detect 1O2 production in PDT and linked the signal to the cytotoxicity, but the irradiation of laser decrease the sensitivity of the detection in vivo. During PDT the high sensitivity probe, Fluoresceinyl Cypridina Luciferin Analog (FCLA), is used to monitor 1O2. In order to avoid the infection of irradiation light, the delayed CL of FCLA is used to indicate 1O2. After recording the delayed CL during PDT and scoring the skin of mice after PDT, the statistic analysis was done. The data shows a remarkable relationship between the score and the CL. the result suggests that the CL can be used as a dose metric in vivo in PDT.

Paper Details

Date Published: 1 May 2007
PDF: 8 pages
Proc. SPIE 6534, Fifth International Conference on Photonics and Imaging in Biology and Medicine, 65342H (1 May 2007); doi: 10.1117/12.741308
Show Author Affiliations
Yanchun Wei, South China Normal Univ. (China)
Da Xing, South China Normal Univ. (China)
Qun Chen, South China Normal Univ. (China)


Published in SPIE Proceedings Vol. 6534:
Fifth International Conference on Photonics and Imaging in Biology and Medicine

© SPIE. Terms of Use
Back to Top